Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam

Biotech company convinces judges over claim construction interpretation | Alnylam “acted as lexicographer” regarding a claim term | Win comes as Moderna suffers economic challenges.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

From the courtroom: Hikma v Amarin SCOTUS oral arguments

30 April 2026 The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.

Americas

CureVac targets Moderna with 10-patent suit over Spikevax

28 April 2026 BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.

Americas

Amneal acquires biopharma ahead of $300bn patent wave

23 April 2026 The US pharma giant is spending up to $1 billion to build an end-to-end biosimilar platform and is counting on a decade of expiring biologic patents to make it pay off.

More features

Squire Patton Boggs promotes partner to head Europe IP&T practice

From the courtroom: Hikma v Amarin SCOTUS oral arguments

Report: 85% of in-house counsel want IP service providers to embrace AI

Moderna loses key mRNA patent in European vaccine fight

Boston-based patent expert departs Mintz for major West Coast firm

Blow for Masimo’s fight with Apple as case against US Customs dismissed

Ligand buys biotech in $739m cash deal with litigation sweetener

CureVac targets Moderna with 10-patent suit over Spikevax

Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam

More on this story

Editor's picks

Editor's picks

More features